Colorectal cancer (CRC) stands as the second most common cause of cancer-related mortality globally and p53, a widely recognized tumor suppressor, contributes to the development of CRC.

Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body's internal, ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.

A new, comprehensive study has uncovered critical insights into the genetic makeup of colorectal cancer (CRC), providing a ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Many people are simply unaware of the existence of the FIT test or underestimate its importance in colorectal cancer ...

Colorectal cancer (CRC) is no laughing matter. It's the second-leading cause of cancer deaths globally, according to the ...

A team of researchers from the First Hospital of Hebei Medical University in China has uncovered intriguing evidence that ...

Researchers also noticed that the mice used as models for Alzheimer’s disease who were given stool transplants from healthy ...

Aug. 14, 2024 — A new study has identified diet-derived molecules called metabolites as main drivers of young-onset colorectal cancer risk, especially those associated with red and processed meat.